Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas

作者：Iriyama Noriyoshi^*; Takahashi Hiromichi; Hatta Yoshihiro; Miura Katsuhiro; Kobayashi Yujin; Kurita Daisuke; Hirabayashi Yukio; Hojo Atsuko; Kodaira Hitomi; Yagi Mai; Kiso Satomi; Uchino Yoshihito; Nakagawa Masaru; Kusuda Machiko; Kobayashi Sumiko; Horikoshi Akira; Kura Yoshimasa; Yamazaki Tetsuo; Sawada Umihiko; Takeuchi Jin

来源：Oncology Reports, 2013, 29(2): 805-811.

DOI：10.3892/or.2012.2143

• peripheral T-cell lymphoma
• dose-intensified CHOP
• autologous hematopoietic stem cell transplantation
• high-dose methotrexate

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of non-Hodgkin lymphomas, often resulting in poor prognoses. The CHOP chemotherapy regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone, has been used previously to treat other types of lymphomas. Here, we examined the efficacy and safety of a dose-intensified CHOP regimen (Double-CHOP), which was followed by autologous stem-cell transplantation (ASCT) or high-dose methotrexate (HDMTX), in PTCL patients. Twenty-eight PTCL patients, who received 3 courses of Double-CHOP at our institution, were retrospectively studied from 1996 to 2012. Patients with anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+)-ALCL) were excluded from this study. The median age of patients was 58 years (range: 17-69). They had low-intermediate (n=11), high-intermediate (n=10) or high (n=7) risk according to the International Prognostic Index (IPI). The overall complete remission (CR) rate following Double-CHOP treatment was 68%. Of the CR patients, 10 successfully tolerated a consolidated high-dose chemotherapy followed by ASCT and 7 received HDMTX. A single case of treatment-related mortality was recorded during the study. On a median 31-month follow-up, the estimated 3- or 5-year overall survival (OS) rates were 68 or 63%, respectively, while 3- or 5-year relapse-free survival (RFS) rates after CR were 60 or 43%, respectively. Although this study included elderly and excluded low-risk IPI and ALK(+)-ALCL patients, OS results were superiorly favourable, indicating the efficacy of this Double-CHOP regimen. However, an effective treatment strategy for refractory or relapsing patients needs to be validated and established.

• 出版日期2013-2